Name of listed company:	Chugai Pharmaceutical Co., Ltd.
Code number:	4519 (Prime Market of Tokyo Stock Exchange)
Head office:	1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO:	Osamu Okuda
Inquiries to:	Toshiya Sasai
	Head of Corporate Communications Dept.
	Tel: +81-(0)3-3273-0554

F. Hoffmann-La Roche Announces Financial Results for fiscal 2022

F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced today its financial results for fiscal 2022 (January 1 – December 31, 2022).

Roche owns 59.89% of Chugai's outstanding shares (61.14% of voting rights) as of the end of December 2022.

Its investor update and presentation materials can be found on its website (<u>https://www.roche.com</u>). Chugai's performance for the period of January 1 to December 31, 2022 is included in the announced Roche Group's results.

Investor Updates

Reporting

###